61
Executive Briefing
At Janssen, the Pharmaceutical Companies of Johnson & Johnson, we're creating a future where disease is a
thing of the past. We tackle society's most pressing health challenges, connecting big ideas to the resources
we need to make them a reality. Our goal is to advance access to good health for all. By seeking out medical
breakthroughs wherever they occur, leveraging internal expertise and embracing external science, we aim to
bring the best solutions to the people who need them.
We focus our efforts and resources where the need is high, the science is compelling and where we have
the greatest opportunity to save and improve lives. We go beyond the medicine by working with patients
through the entire process to ensure the best possible experience and health outcomes.
We are driven by our belief that "patients are waiting" and there is no time to waste.
Learn more: www.janssen.com
ix. Schreiner, P., Neurath, M. F., Ng, S. C., El-Omar, E. M., Sharara, A. I.,
Kobayashi, T., Hisamatsu, T., Hibi, T., & Rogler, G. (2019). Mechanism-
Based Treatment Strategies for IBD: Cytokines, Cell Adhesion
Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory intestinal
diseases, 4(3), 79–96, pg 88. https://doi.org/10.1159/000500721
x. Lin, L., & Zhang, J. (2017). Role of intestinal microbiota and metabolites
on gut homeostasis and human diseases. BMC immunology, 18(1), 2,
pg 1. https://doi.org/10.1186/s12865-016-0187-3
xi. Groschwitz, K. R., & Hogan, S. P. (2009). Intestinal barrier function:
molecular regulation and disease pathogenesis. The Journal of allergy
and clinical immunology, 124(1), 3–22, pg. 10.
https://doi.org/10.1016/j.jaci.2009.05.038
xii. Roda, G., Chien Ng, S., Kotze, P.G. et al. Crohn's disease. Nat Rev Dis
Primers 6, 22 (2020), pg. 4. https://doi.org/10.1038/s41572-020-0156-2
xiii. Groschwitz, K. R., & Hogan, S. P. (2009). Intestinal barrier function:
molecular regulation and disease pathogenesis. The Journal of allergy
and clinical immunology, 124(1), 3–22. pg. 14.
https://doi.org/10.1016/j.jaci.2009.05.038
xiv. Roda, G., Chien Ng, S., Kotze, P.G. et al. Crohn's disease. Nat Rev Dis
Primers 6, 22 (2020). Pg. 4. https://doi.org/10.1038/s41572-020-0156-2
xv. Roda, G., Chien Ng, S., Kotze, P.G. et al. Crohn's disease. Nat Rev Dis
Primers 6, 22 (2020). Pg. 7. https://doi.org/10.1038/s41572-020-0156-2
xvi. Roda, G., Chien Ng, S., Kotze, P.G. et al. Crohn's disease. Nat Rev Dis
Primers 6, 22 (2020). Pg. 11.
https://doi.org/10.1038/s41572-020-0156-2
xvii. Roda, G., Chien Ng, S., Kotze, P.G. et al. Crohn's disease. Nat Rev Dis
Primers 6, 22 (2020). Pg. 5. https://doi.org/10.1038/s41572-020-0156-2
xviii. Groschwitz, K. R., & Hogan, S. P. (2009). Intestinal barrier function:
molecular regulation and disease pathogenesis. The Journal of allergy
and clinical immunology, 124(1), 3–22. pg. 7.
https://doi.org/10.1016/j.jaci.2009.05.038
xvii. Schreiner, P., Neurath, M. F., Ng, S. C., El-Omar, E. M., Sharara, A. I.,
Kobayashi, T., Hisamatsu, T., Hibi, T., & Rogler, G. (2019). Mechanism-
Based Treatment Strategies for IBD: Cytokines, Cell Adhesion
Molecules, JAK Inhibitors, Gut Flora, and More. Inflammatory intestinal
diseases, 4(3), 79–96. pg. 84. https://doi.org/10.1159/000500721
xix. Wehkamp, J. & Stange, E. F. (2020) An Update Review on the Paneth
Cell as Key to Ileal Crohn's Disease. Frontiers in Immmunolgy, 11: 646.
https://doi.org/10.3389/fimmu.2020.00646
We are Janssen
Immunology.
Innovating for patients
around the world.
21 YEARS 5 TREATMENTS 30 INDICATIONS 5 million PATIENTS TREATED
Join us at careers.jnj.com
